Search Results
Your search for ,waY matches 3896 pages
Showing 551 - 600Novel DELFI AI Blood Test May Aid in Detecting Hepatocellular Carcinoma
A novel artificial intelligence (AI) blood testing technology—known as DELFI (DNA evaluation of fragments for early interception)—may successfully detect more than 80% of hepatocellular carcinomas, according to a new study published by Foda et al in Cancer Discovery. The findings were also...
Novel Research Suggests New Way to Target Mantle Cell Lymphoma Using FOXO1 Inhibitors
Preclinical research has shown that mantle cell lymphoma is so critically dependent on the FOXO1 protein that by blocking its activity with an experimental drug, the cancer’s growth may be slowed, according to a new study published by Jang et al in the Journal of Clinical Investigation....
Study Examines Coping Strategies Used by Caregivers of Patients Undergoing Stem Cell Transplants
November is Caregiver Awareness Month, and timely findings from a study published by Amonoo et al in the journal Blood Advances suggested that, among caregivers of patients undergoing a stem cell transplant, how someone approaches coping can influence the levels of anxiety, depression, and poor...
High Sugar Consumption May Be Linked to Increased Risk of Premature Aging in Pediatric Cancer Survivors
Survivors of pediatric cancer who consumed more total sugar, added sugar, and sugar-sweetened beverages had more aging-related health conditions than survivors who consumed less sugar, according to a new study presented by Lan et al at the American Association for Cancer Research (AACR) Special...
Breast Cancer Advocate and Chief of Surgical Oncology at Howard University, Lori Wilson, MD, FACS, Dies
Lori Wilson, MD, FACS, was the first woman to hold the surgical oncology division chief position at Howard University Hospital and the first woman to be promoted to full professor in surgery at Howard University College of Medicine. Known as a fierce advocate for patients with cancer in underserved ...
A Laryngectomy Altered How I See Myself in the World
There is a 2-decades-long separation between the time I was diagnosed with oropharyngeal squamous cell carcinoma in 1996 and my laryngectomy in 2016. The surgery was necessary because of the long-term damage to my larynx from the radiation therapy I received. In 1996, I had a low-grade sore throat...
Report on Brain Cancer: Crisis in the Childhood and Adolescent Cancer Community
A RECENT REPORT published in Neuro-Oncology1 exposes an alarming reality for children, adolescents, and families facing pediatric brain cancer across the country. The Pediatric Brain Tumor Foundation (PBTF) funded this groundbreaking report by the Central Brain Tumor Registry of the United States...
C.S. Pramesh, MS, FRCS, Seeks to Bring Equity to India’s Sprawling Cancer Care System
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with C.S. Pramesh, MS, FRCS, Director of the Tata Memorial Hospital and Professor and Head of Thoracic Surgery at the Tata Memorial Centre, Mumbai, India. Dr. Pramesh is the Convener of the...
Expert Point of View: Benjamin Movsas, MD
Benjamin Movsas, MD, who was not involved in the phase II trial of prophylactic radiation for bone metastases, commented: “I thought this was a very important study. We will need to see the details in the final paper, but this approach could make a meaningfuldifference in the quality of life for...
My White Coat Doesn’t Fit
There I was, crying once again all the way from the hospital’s parking lot to my apartment, into the shower, and while trying to fall asleep. This had become the norm during my internal medicine residency. For years, I tried hard every day to be someone else to fit in. It started with off-hand...
Expert Point of View: Glenn J. Hanna, MD, and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Prolonging Remission in Anti–PD-1 Refractory Melanoma With Tumor-Infiltrating Lymphocyte Therapy
For the first time in a multicenter randomized trial, T-cell therapy has been shown to improve outcomes in a solid tumor. In the phase III M14TIL trial, first-line or second-line treatment with tumor-infiltrating lymphocytes (TIL) led to a 50% reduction in disease progression or death from advanced ...
Global Effort to Eliminate Cervical Cancer: HPV Vaccinations Are Steadily Increasing in the United States, but Barriers Still Exist
To achieve its goal of eliminating cervical cancer, the World Health Organization (WHO) is calling on all countries “to reach and maintain an incidence rate of below 4 per 100,000 women.” Doing so would depend on the following: A total of 90% of girls being fully vaccinated against human...
With Newer Therapies, AML Diagnosis and Prognosis Evolve
For many years, treatment options for acute myeloid leukemia (AML) were limited mainly to the 7 + 3 regimen. However, more recently, a mini-explosion of AML therapies aimed at newly identified genetic targets makes discussions about treatment of this disease much more complicated. In fact, these...
Study Finds Nearly Half of Black Women With Metastatic Breast Cancer Never Receive Information About Clinical Trial Participation
When Stephanie L. Walker, RN, was diagnosed with metastatic breast cancer in 2015, she was not given information about an appropriate clinical trial or help navigating her way through the financial difficulties she was having after a stroke from complications of the cancer forced her to leave her...
How to Advance Antiracist Approaches to Patient Engagement in AYA Oncology and Research
Among the topics discussed at the 4th Global Adolescent and Young Adult Cancer Congress held online in December 2021 was the urgent need for clinicians, researchers, and advocates in adolescent and young adult (AYA) oncology to join forces to eradicate racist approaches to patient engagement in...
Effect of Smartphone Psychotherapy Apps on Fear of Recurrence Among Young Breast Cancer Survivors
In a Japanese trial (J-SUPPORT 1703) reported in the Journal of Clinical Oncology, Akechi et al found that 8-week use of smartphone psychotherapy apps was associated with significant benefits in reducing the fear of recurrence in breast cancer survivors aged 20 to 49 years. Study Details In the...
Preliminary Results From ARROS-1 Phase I Clinical Trial Suggest That NVL-520 May Be Well Tolerated and Active in NSCLC
Preliminary data from a phase I clinical trial of the ROS1 inhibitor NVL-520 to treat patients with non–small cell lung cancer (NSCLC) and other solid tumors suggested that it may have the potential to both halt tumor growth by inhibiting a cancer-causing gene change and reach cancer cells within...
Small Study of Experimental Drug to Treat Liver Cancer Shows Evidence of Activity With Manageable Side Effects
A new drug designed to inhibit an enzyme that plays a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer and up to three lines of previous unsuccessful treatment, according to a new study published by Reig et al ...
Expert Point of View: Glenn J. Hanna, MD and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Legal and Ethical Use of Complementary and Alternative Medicine Interventions in Oncology
In addition to, or instead of, receiving therapies that are the standard of care, patients with cancer sometimes request to receive complementary (therapies used in conjunction with standard cancer treatment) and alternative (nonstandard treatments used in place of standard cancer treatment)...
Sexual Side Effects of Cancer Treatment Often Unaddressed With Female Patients
A new study has found that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs. Among patients receiving brachytherapy for prostate or cervical cancer at a high-volume cancer...
Leader in Genitourinary Oncology, Nicholas J. Vogelzang, MD, FACP, FASCO, Dies at 72
Nicholas J. Vogelzang, MD, FACP, FASCO, an expert in the treatment of patients with renal cell carcinoma, died on September 20, 2022. Dr. Vogelzang was 72 years old. Son of a Preacher Dr. Vogelzang was born on December 13, 1949, in Holland, Michigan, the oldest of seven children, in a close-knit...
A Urologic Surgeon Shares His Insights on Robotic Radical Prostatectomy
In 2000, the da Vinci Surgical System broke new ground by becoming the first robotic surgery system approved by the U.S. Food and Drug Administration for general laparoscopic surgery. In its early years, robot-assisted radical prostatectomy was characterized by some in the surgical community as an...
Clinical and Translational Researcher Rossana Berardi, MD, Works to Overcome the Gender Gap in Oncology in Italy
In our continuing effort to connect and learn more about our international oncology colleagues, The ASCO Post recently spoke with Rossana Berardi, MD, Professor in Medical Oncology and Director of the Postgraduate School of Oncology at the Università Politecnica Marche, Ancona, Italy, where she is...
Providing a Tailored Approach to Prostate Cancer Care for Gay and Bisexual Men
It is estimated that one in eight men will be diagnosed with prostate cancer in his lifetime. The disease is so prevalent, and other than skin cancer, it is the most common cancer diagnosed in American men. According to the American Cancer Society, this year, about 268,490 new cases of prostate...
Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
Future Leaders Selected to Advance Gender Equality Through the Leadership Programme for Women in Oncology
The first 10 participants in the new Leadership Programme for Women in Oncology have been announced. The program, a joint endeavour from ASCO and City Cancer Challenge Foundation (C/Can), seeks to address the specific challenges and barriers faced by women leaders in oncology and strengthen the...
For William L. Dahut, MD, a Career of Service in Oncology
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with William L. Dahut, MD, who is currently serving as Chief Scientific Officer for the American Cancer Society (ACS). In this role, Dr. Dahut manages all pieces of the organization’s discovery work,...
A Call for Creativity: The Shades of Gray in Delivery of Goal-Concordant Care
I continue to be struck by the creativity of medical oncologists. The reimagining of dosing, duration, or regimen composition to respond to patient symptoms or preferences is like a master chef in the kitchen. Although standardization has, with good reason, become the paragon, delivering...
PCS5 Trial: Long-Term Outcomes of Moderately Shortened Radiation Course for High-Risk Prostate Cancer
A randomized study has confirmed that patients with high-risk prostate cancer can be treated with 5 vs 8 weeks of radiation therapy. The phase III clinical trial is the first to confirm the safety and efficacy of a moderately shortened course of radiation exclusively for patients with high-risk...
Study Identifies How Cancer-Causing Gene Might Regulate Genetic Variation in Prostate Cancer
Researchers at the Barts Cancer Institute at the Queen Mary University of London, the Italian Institute for Genomic Medicine, and the University of Milan may have identified a novel role for a cancer-causing gene in controlling an important genetic process that underpins genetic variation in...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
Datopotamab Deruxtecan Shows Activity in Advanced Triple-Negative Breast Cancer
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer, according to early findings from the phase I TROPION-PanTumor01 trial presented...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the BEGONIA trial,1 Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, called the activity of the combination of durvalumab and datopotamab deruxtecan (Dato-DXd) “notable,” with a 74% response rate overall,...
Effect of Social Factors on Cancer Screening Rates Across U.S. Counties
Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
Mechanism Linking Air Pollution to Lung Cancer Identified
Although air pollution is associated with lung cancer, not much has been known about how one leads to the other. For the first time, researchers have identified a mechanism by which particulate matter in the air triggers non–small cell lung cancer (NSCLC) in people who have never smoked. Moreover,...
Saul A. Rosenberg, MD, FASCO, a Pioneer in the Field of Lymphoma, Dies at 95
For anacademic oncologist, there is no greater reward than to be part of the clinical research that turns a fatal cancer into a highly treatable disease. Saul A. Rosenberg, MD, FASCO, was one such researcher who pioneered advances in the diagnosis, treatment, and understanding of lymphoma,...
The Development of Geriatric Oncology in France: An Outside View
With the aging of the world population, geriatric oncology is becoming a mainstay. Over the past year in The ASCO Post, we published a couple of articles on the history of oncology, including one on the history of geriatric oncology in the United States and Europe. Our goal was to promote a...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Research Examines a New Tool for Discovering Cancer-Driving Structural Variations
An advanced software tool for analyzing DNA sequences from tumor samples has uncovered new, likely cancer-driving genes. In a study, Weill Cornell Medicine researchers designed the software, known as CSVDriver, to map and analyze the locations of large mutations, known as structural variants, in...
Study Finds High-Intensity Intervention Helped One-Third of Participants in Lung Cancer Screening Program to Quit Smoking
Despite significant advancements in cancer therapy, the number-one stopper of lung cancer remains the most basic intervention: quitting smoking. Unfortunately, for long-term smokers, that intervention can sometimes be the most challenging. According to data presented during the International...
Study Focuses on Molecular Details of Precancerous Clonal Outgrowth in Blood Cells
A common, spontaneous mutation in blood stem cells, which has been linked to a higher risk of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce, according to a study co-led by...
Unhealthy Gut May Set the Stage for Breast Cancer to Spread, Preclinical Research Reveals
An unhealthy gut triggers changes in normal breast tissue that may help breast cancer metastasize, according to new, early research from the University of Virginia (UVA) Cancer Center published by Feng et al in Cancer Immunology Research. The researchers found that when the gut microbiome is...
Total Cost of Cancer Care May Be Reduced With Lower-Cost Alternate Drugs Without Compromising Quality of Care
Substituting biosimilars, generics, and clinically appropriate lower-cost drugs for established, costlier drugs was shown to be an effective way to reduce the total cost of care, by 5% or so, while maintaining the quality of care for patients with cancer. Even small shifts toward lower-cost drugs...
A Physicist Father Inspired a Love of Science in Oncology Researcher Stanton L. Gerson, MD
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stanton (“Stan”) L. Gerson, MD, Dean and Senior Vice President for Medical Affairs, School of Medicine, and Acting Director of the Case Comprehensive Cancer Center and National Center for...
Determining Prognosis in Aggressive Lymphomas: Integrating Liquid Biopsy Into Imaging Assessment
The incorporation of blood-based measurements—ie, “liquid biopsies”—into imaging assessment may refine the accuracy of prognosis in aggressive lymphomas, as described by David Kurtz, MD, PhD, Assistant Professor in the Division of Oncology, Stanford University Medical Center, in a talk at the 2022...
